Both the SHP2 inhibitor RMC4550 and the JAK2 inhibitor decreased RAS-GTP levels in myeloproliferative neoplasm cells, and their combined employment enhanced ERK inactivation and increased apoptosis37. This evidence concerns the gene JAK2 and myeloproliferative disorder.